Breast Cancer

Results from the DESTINY-Breast06 trial led to the approval of T-DXd for patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer.

Data show a trend towards a reduced risk of death with fulvestrant vs anastrozole among patients with nonvisceral disease in the phase 3 FALCON trial.

Acalabrutinib improves efficacy in high-risk patients like those with TP53 mutations, those with complex cytogenetics, and those with high proliferative rates in MCL.

The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.

Data from the TROPION-Breast01 trial support the FDA approval of datopotamab deruxtecan for those with metastatic HR–positive, HER2-negative breast cancer.

Data support the IGG signature, especially its key gene subset, as a potential marker of sustained antitumor activity in breast cancer.

The use of artificial intelligence led to a higher rate of breast cancer detection as an improvement for mammography screening compared with standard detection methods.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

The World Health Organization has approved emiltatug ledadotin as XMT-1660’s international nonproprietary name.

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

Phase 1 data may support further development of ZN-1041 combination therapies for a larger breast cancer population.

A study of patients who received the KEYNOTE-522 regimen showed an improved pathologic complete response in real-world data vs what study data showed.

A phase 1/2 study showed that treatment with cyclophosphamide, SV-BR-1-GM, and retifanlimab yields favorable survival data in heavily pretreated patients with breast cancer.

Broader margins used in lumpectomies can lead to a reduced radiation target area in patients with breast cancer, according to results from a study presented at the 2024 SABCS.

In a From All Angles program, a patient and her treating physician spoke about the initial diagnosis, care coordination, communication, and the adverse effects observed.

Ivonescimab with chemotherapy elicited a median progression-free survival of 9.36 months in patients with locally advanced unresectable or metastatic triple-negative breast cancer.

Phase 1b/2 data show antitumor activity with zanidatamab/evorpacept, including among heavily pretreated patients with HER2-low metastatic breast cancer.

Phase 2 data indicate that CD8 status may serve as a biomarker for predicting treatment efficacy with tislelizumab-based treatment in TNBC.

The FITWISE clinical trial assessed the safety and tolerability of breast cancer treatments when patients use tirzepatide.

The first stage of a phase 2 trial evaluating neoadjuvant SHR-A1811 in breast cancer meets its primary end point of ORR.

LumiSystem prompted the removal of a median of 10.5cc extra tumor margin tissue in patients with breast cancer and did not significantly affect satisfaction outcomes.

Data from a phase 1b/2 study show a 78.6% ORR in patients with metastatic triple-negative breast cancer treated with PM8002/BNT327 plus nab-paclitaxel.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.

The phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer.